Physician profile
Ashbeel Samuel
NPI 1659728004
$806.32
in general payments reported to CMS, 2019-2025
10 companies · $44.59 in 2025
The $44.59 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $88.47 · 2022: $125 · 2023: $251 · 2024: $181 · 2025: $44.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $440 · Education: $35.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $440.35 |
| Education | $35.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $169.35 | 2023 | Monoferric |
| Kestra Medical Technology Services, INC. | $161.29 | 2024-2025 | Assure Wcd |
| Novo Nordisk INC | $125.00 | 2022 | |
| Radius Health, INC. | $96.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $94.94 | 2023-2024 | Xarelto |
| Abbott Laboratories | $88.47 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.47 | 2024 | Andexxa |
| Amgen INC. | $20.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $16.21 | 2023 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.80 | 2024 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashbeel Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.